Suppr超能文献

地塞米松调节人无色素睫状上皮(HNPE)细胞中的内皮素-1和内皮素受体。

Dexamethasone regulates endothelin-1 and endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells.

作者信息

Zhang Xinyu, Krishnamoorthy Raghu R, Prasanna Ganesh, Narayan Santosh, Clark Abbot, Yorio Thomas

机构信息

Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, TX 76107, USA.

出版信息

Exp Eye Res. 2003 Mar;76(3):261-72. doi: 10.1016/s0014-4835(02)00323-8.

Abstract

Endothelin-1 (ET-1) lowers intraocular pressure (IOP) in animal models by regulating aqueous humour dynamics through both inflow and outflow mechanisms. Moreover, ET's concentration is elevated in glaucoma patients and in animal models of glaucoma. Glucocorticoid therapy often can lead to increase IOP in susceptible individuals including patients with primary open angle glaucoma (POAG). In this study, we examined the effects of dexamethasone (Dex), a frequently used anti-inflammatory glucocorticoid, on the synthesis and release of endothelin-1 and on the expression of endothelin receptors in human non-pigmented ciliary epithelial (HNPE) cells, an established source for ET-1 in the anterior chamber. As measured by ET-1 immunoreactivity, ET-1 was concentration-dependently increased following 24hr Dex treatment, with a maximum concentration (100 nM) causing a threefold increase of ET-1 release. Western blot analysis of HNPE cells showed the expression of endothelin receptor A (ET(A)) and endothelin receptor B (ET(B)) with approximate molecular weights of 40 kDa. Dex treatment decreased ET(A) receptor expression at all Dex doses, but up-regulated ET(B) receptors with 10nM Dex having the greatest effect. Quantitative PCR demonstrated that Dex also increased the mRNA of pre-pro-ET-1 (ppET-1) and ET(B) but decreased the mRNA of ET(A). RU486, a glucocorticoid receptor antagonist, was able to block Dex's actions on ET release and ET(B) receptor expression, but did not block its action on ET(A) receptor expression. Endothelin receptors were minimally expressed in HNPE cells as determined in binding experiments (B(max): ET(A) 17, ET(B) 25 fmolmg(-1) membrane protein). However Dex treatment stimulated a dramatic increase in ET(B) receptor density while decreasing ET(A) receptors (B(max): ET(A) 11, ET(B) 116 fmolmg(-1) membrane protein). The regulation of endothelin and its receptors could be a novel mechanism associated with glucocorticoid's effects on intraocular pressure. The increase in ET-1 and disproportionate regulation in ET receptor expression by Dex could promote dysregulation in ET's mechanism on both inflow and outflow, thus affecting aqueous humour dynamics in the anterior chamber of the eye.

摘要

内皮素 -1(ET -1)在动物模型中通过调节房水动力学的流入和流出机制来降低眼压(IOP)。此外,青光眼患者和青光眼动物模型中ET的浓度会升高。糖皮质激素治疗通常会导致易感个体眼压升高,包括原发性开角型青光眼(POAG)患者。在本研究中,我们检测了常用的抗炎糖皮质激素地塞米松(Dex)对人非色素睫状上皮(HNPE)细胞中内皮素 -1的合成与释放以及内皮素受体表达的影响,HNPE细胞是前房内ET -1的既定来源。通过ET -1免疫反应性检测发现,24小时Dex处理后ET -1呈浓度依赖性增加,最大浓度(100 nM)导致ET -1释放增加三倍。对HNPE细胞进行蛋白质印迹分析显示,内皮素受体A(ET(A))和内皮素受体B(ET(B))的表达,其近似分子量为40 kDa。Dex处理在所有Dex剂量下均降低ET(A)受体表达,但上调ET(B)受体,其中10 nM Dex的作用最为显著。定量PCR表明,Dex还增加了前体 - ET -1(ppET -1)和ET(B)的mRNA,但降低了ET(A)的mRNA。糖皮质激素受体拮抗剂RU486能够阻断Dex对ET释放和ET(B)受体表达的作用,但不能阻断其对ET(A)受体表达的作用。结合实验表明,HNPE细胞中内皮素受体表达极低(B(max):ET(A) 17,ET(B) 25 fmolmg(-1)膜蛋白)。然而,Dex处理刺激ET(B)受体密度显著增加,同时降低ET(A)受体(B(max):ET(A) 11,ET(B) 116 fmolmg(-1)膜蛋白)。内皮素及其受体的调节可能是与糖皮质激素对眼压影响相关的一种新机制。Dex导致ET -1增加以及ET受体表达的不成比例调节,可能会促进ET在流入和流出机制上的调节失调,从而影响眼前房的房水动力学。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验